| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| Other Sizes |
| Targets |
Tectoridin targets estrogen and thyroid hormone receptors, acting as a phytoestrogen that activates both receptors. It exerts estrogenic effects via ER-dependent genomic pathways and GPR30-dependent non-genomic pathways. The compound also acts as a lens aldose reductase inhibitor and inhibits cyclooxygenase-2 (COX-2) induction, contributing to its anti-inflammatory and hypoglycemic activities.
|
|---|---|
| ln Vitro |
In contrast to 17β-estradiol and genistein, irisin binds to ERα very weakly [2]. Irisin has the ability to transactivate estrogen response elements, produce MCF-7 cell proliferation, cause strong estrogenic effects, and return cell populations to the S phase in livestock that have been starved [2]. The estrogenic actions of irisin are strongly inhibited by U0126 (1/2-fold MEK) inhibition. Irisin has the ability to increase ERK1/2 phosphorylation, but it has no effect on ERα Ser phosphorylation (118). Additionally, tectoridin raises the amount of cAMP inside cells [2].
In vitro, tectoridin exhibits antioxidant, anti-inflammatory, hepatoprotective, and hypoglycemic activities. It inhibits lens aldose reductase and cyclooxygenase-2 induction. The compound activates estrogen and thyroid hormone receptors. It inhibits the production of prostaglandin E2 (PGE2) and modulates oxidative stress pathways and cellular signaling cascades. Tectoridin also possesses anticancer activity. |
| ln Vivo |
In vivo, tectoridin has demonstrated pharmacological effects including hypoglycemic, anti-cancer, anti-inflammatory, antioxidant, and hepatoprotective activities. As a phytoestrogen, it exerts estrogenic effects through both genomic and non-genomic pathways. The compound has been studied for its potential in liver health, cancer prevention, and metabolic disorders. Its antioxidant properties contribute to its hepatoprotective effects.
|
| Enzyme Assay |
In vitro enzyme assays for tectoridin measure its inhibition of lens aldose reductase and cyclooxygenase-2 (COX-2). The enzyme is incubated with its substrate and varying concentrations of the compound. Enzyme activity is measured by spectrophotometric or chromatographic methods. IC50 values are calculated from dose-response curves. Receptor binding assays for estrogen and thyroid hormone receptors can also be performed using radioligand displacement techniques.
|
| Cell Assay |
In vitro cell-based assays for tectoridin use various cell lines to assess its biological activities. Estrogenic activity is assessed using GH3 rat pituitary cells or MCF-7 human breast cancer cells in reporter assays. Anti-inflammatory activity is measured by assessing PGE2 production. Antioxidant activity is evaluated by measuring reactive oxygen species (ROS) levels or using antioxidant response element (ARE) reporter assays. Cell viability and proliferation are assessed using MTT or other assays.
|
| Animal Protocol |
In vivo animal models for tectoridin include models of diabetes (for hypoglycemic effects), cancer (for anticancer effects), and liver disease (for hepatoprotective effects). The compound is administered orally or intraperitoneally, and its effects on blood glucose, tumor growth, liver enzymes, and inflammatory markers are evaluated. Pharmacodynamic studies measure target engagement and pathway modulation.
|
| ADME/Pharmacokinetics |
Tectoridin has a molecular formula of C22H22O11 and a molecular weight of 462.40. The compound is a naturally occurring isoflavone glycoside. It is stored as a powder at -20°C. Pharmacokinetic properties including absorption, distribution, metabolism, and excretion are documented in research publications. The compound is soluble in DMSO and other organic solvents.
|
| Toxicity/Toxicokinetics |
The toxicity profile of tectoridin is favorable, as it is a natural compound with a long history of use in traditional medicine. It is generally well-tolerated at therapeutic doses. High doses may cause gastrointestinal discomfort. The compound is not known to be genotoxic or carcinogenic at relevant exposure levels. It is used for research purposes and is not approved for clinical use.
|
| References | |
| Additional Infomation |
Iris glycoside is a glycosyl isoflavone formed by the substitution of irisin at the 7-position by a β-D-glucopyranose residue via a glycosidic bond. It is a plant metabolite. Iris glycoside is a hydroxy isoflavone, a methoxy isoflavone, a monosaccharide derivative, and a 7-hydroxy isoflavone 7-O-β-D-glucoside. It is functionally related to irisin. Iris glycoside has been found in plants of the genus Iris (such as iris and iris flowers) and other organisms with relevant data.
Tectoridin is a naturally occurring isoflavone glycoside found in plants like Belamcanda chinensis and Maackia amurensis. It is also known as tectorigenin 7-glucoside, shekanin, and shekkanin. The compound is a phytoestrogen that activates estrogen and thyroid hormone receptors. It has diverse biological activities including antioxidant, anti-inflammatory, hepatoprotective, hypoglycemic, and anticancer effects. Tectoridin is used for research purposes in phytochemical and biochemical studies. |
| Molecular Formula |
C22H22O11
|
|---|---|
| Molecular Weight |
462.407
|
| Exact Mass |
462.116
|
| CAS # |
611-40-5
|
| PubChem CID |
5281810
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
798.1±60.0 °C at 760 mmHg
|
| Melting Point |
261.8-263.2ºC
|
| Flash Point |
279.7±26.4 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.695
|
| LogP |
0.29
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
721
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C=C2C(=C1O)C(=O)C(=CO2)C3=CC=C(C=C3)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
CNOURESJATUGPN-UDEBZQQRSA-N
|
| InChi Code |
InChI=1S/C22H22O11/c1-30-21-13(32-22-20(29)19(28)17(26)14(7-23)33-22)6-12-15(18(21)27)16(25)11(8-31-12)9-2-4-10(24)5-3-9/h2-6,8,14,17,19-20,22-24,26-29H,7H2,1H3/t14-,17-,19+,20-,22-/m1/s1
|
| Chemical Name |
7-(beta-D-Glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one
|
| Synonyms |
Shekanin Tectoridin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~540.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1626 mL | 10.8129 mL | 21.6258 mL | |
| 5 mM | 0.4325 mL | 2.1626 mL | 4.3252 mL | |
| 10 mM | 0.2163 mL | 1.0813 mL | 2.1626 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
